Verheijen F W, Palmeri S, Hoogeveen A T, Galjaard H
Eur J Biochem. 1985 Jun 3;149(2):315-21. doi: 10.1111/j.1432-1033.1985.tb08928.x.
Supernatant of homogenized human placenta hardly contains lysosomal neuraminidase activity. It is, however, possible to generate remarkably high activity by concentration of a partially purified glycoprotein fraction. This activity is labile to dilution, but can be stabilized by incubation at 37 degrees C and acid pH. Using beta-galactosidase specific affinity chromatography and immunotitration, we show that the activated and stabilized human lysosomal neuraminidase exists in a complex with beta-galactosidase. Sucrose density gradient centrifugation experiments demonstrate that the neuraminidase activity is exclusively present in a high density multimeric form of beta-galactosidase. The formation of multimeric forms of beta-galactosidase is known to require a 32000-Mr 'protective' protein. Monospecific antibodies against this 'protective' protein were purified from a conventional antiserum containing a mixture of antibodies against the 64000-Mr beta-galactosidase protein and against the 32000-Mr 'protective' protein, using a nitrocellulose blot immunoaffinity purification procedure. Immunotitration experiments with these antibodies show that the 32000-Mr 'protective' protein is present both in association with the beta-galactosidase multimer and with the high-density multimeric form together with neuraminidase. Our data further suggest that association of the 32000-Mr 'protective' protein and another yet unidentified subunit is essential for the catalytic activity of lysosomal neuraminidase. These results explain the absence of neuraminidase activity in the autosomal recessive human lysosomal storage disorder galactosialidosis, where the 32000-Mr 'protective' protein is known to be absent.
人胎盘匀浆的上清液几乎不含有溶酶体神经氨酸酶活性。然而,通过浓缩部分纯化的糖蛋白组分可以产生显著高的活性。这种活性对稀释不稳定,但可通过在37℃和酸性pH下孵育来稳定。使用β-半乳糖苷酶特异性亲和色谱和免疫滴定法,我们表明活化并稳定的人溶酶体神经氨酸酶与β-半乳糖苷酶形成复合物存在。蔗糖密度梯度离心实验表明神经氨酸酶活性仅存在于β-半乳糖苷酶的高密度多聚体形式中。已知β-半乳糖苷酶多聚体形式的形成需要一种分子量为32000的“保护”蛋白。使用硝酸纤维素印迹免疫亲和纯化程序,从含有针对分子量为64000的β-半乳糖苷酶蛋白和分子量为32000的“保护”蛋白的抗体混合物的常规抗血清中纯化出针对这种“保护”蛋白的单特异性抗体。用这些抗体进行的免疫滴定实验表明,分子量为32000的“保护”蛋白既与β-半乳糖苷酶多聚体结合,也与高密度多聚体形式以及神经氨酸酶一起存在。我们的数据进一步表明,分子量为32000的“保护”蛋白与另一个尚未鉴定的亚基的结合对于溶酶体神经氨酸酶的催化活性至关重要。这些结果解释了常染色体隐性人类溶酶体贮积症半乳糖唾液酸沉积症中神经氨酸酶活性的缺失,已知该病症中不存在分子量为32000的“保护”蛋白。